|
Lymphoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1.
|
24136166 |
2013 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further, transient Flag-LMP1 expression in a B-lymphoma cell line transduces signals that upregulate TRAF1 levels but does not alter JAK3 levels or activation state.
|
11739714 |
2002 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To characterize the oncogenic role of simian EBV infection for lymphomagenesis during SIV infection, expression of the EBV-encoded latent membrane protein-1 (LMP-1) was analyzed in malignant lymphomas of SIV-infected rhesus macaques.
|
11505452 |
2001 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, these data suggest that an anti-LMP1 sFv used in combination with conventional chemotherapy may be useful for gene therapy of EBV-associated lymphomas in immunocompromised patients.
|
9930317 |
1998 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.
|
22341446 |
2012 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is crucial for B cell transformation and oncogenesis of other EBV-related malignancies, such as nasopharyngeal carcinoma and T/NK lymphoma.
|
26819314 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, these data suggest that immunotherapy targeting LMP1 in EBV-associated NK lymphomas and CAEBV might serve as an alternative treatment modality.
|
16479544 |
2006 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To further investigate the potential relationship of del-LMP-1 to EBV-LPDs associated with immunosuppression or immunodeficiency, we studied 39 EBV-associated lymphoproliferations (10 benign, 29 malignant) from four distinct clinical settings: posttransplant (4 malignant, 1 reactive); HIV+ (18 malignant, 2 reactive); nonimmunodeficiency malignant lymphoma (ML) (7 cases); and sporadic EBV infection with lymphoid hyperplasia (7 cases).
|
8704180 |
1996 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epstein-Barr virus latent membrane protein 1 (LMP1) is expressed in multiple human malignancies, including nasopharyngeal carcinoma and Hodgkin and immunosuppression-associated lymphomas.
|
28835489 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
LMP1-mediated signaling through the TRAF system has a role in the pathogenesis of the EBV-positive lymphomas that arise in immunosuppressed patients.
|
9580648 |
1998 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, transfection with LMP1 expression vector into a human B lymphoma cell line, Daudi, led to p40 production with nuclear factor (NF)-kappaB activation.
|
9837745 |
1998 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gene expression levels of LMP-1, LMP-2A, and LMP-2B and EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNA-LP were monitored by real-time quantitative-polymerase chain reaction (qRT-PCR) in cells from nine EBV-induced lymphomas and in matched lymphocytes from healthy subjects.
|
26548532 |
2016 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Deletion variants within the NF-kappa B activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations.
|
8562956 |
1996 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The Epstein-Barr virus latent membrane protein 1 (LMP-1) is essential for virus-induced B cell immortalization and can protect B lymphoma cell lines from apoptosis signals in vitro via induction of cellular Bcl-2 expression.
|
9367385 |
1997 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Because T cells specific for these antigens are present with low frequency and may be rendered anergic by the tumors that express them, we expanded LMP-cytotoxic T lymphocytes (CTLs) from patients with lymphoma using autologous dendritic cells and EBV-transformed B-lymphoblastoid cell lines transduced with an adenoviral vector expressing either LMP2 alone (n = 17) or both LMP2 and ΔLMP1 (n = 33).
|
24344220 |
2014 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies identifying a characteristic 30-base pair deletion within the 3' end of latent membrane protein-1 (del-LMP-1) in other EBV-associated lymphomas suggested a pathogenetic role for del-LMP-1 in those neoplasms.
|
9720504 |
1998 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Nucleotide sequence analysis indicated that the homologies of EBV LMP1 genes in the induced malignant lymphomas and undifferentiated carcinomas to the B95-8 cell gene were around 96% and 99% respectively.
|
9829857 |
1998 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Because the LMP gene has transforming potential, our findings support the concept of a pathoetiologic role for EBV in a proportion of CD30-positive ALC lymphomas.
|
1668608 |
1991 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, IL-10 could induce the expression of LMP-1 in tonsillar B cells infected with the nontransforming, EBNA-2-deficient EBV strain P3HR1 and enhance LMP-1 expression in 2 EBV-positive NK lymphoma lines.
|
16332968 |
2006 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In all four patients, the lymphoma was associated with Epstein-Barr virus infection, detected by EBER in situ hybridization and the latency I phenotype as defined by lack of expression of LMP1.
|
15104301 |
2004 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These data suggest new functions of the N terminus and transmembrane domains in LMP1 intra- and extracellular trafficking that are likely downstream of an interaction with CD63.<b>IMPORTANCE</b> EBV infection contributes to the development of cancers, such as nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin's disease, and posttransplant lymphomas, in immunocompromised or genetically susceptible individuals.
|
29950415 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the latent membrane protein-1 (LMP1) of the Epstein-Barr virus (EBV) is believed to be important for the transformation of germinal centre (GC) B cells, the precise contribution of this viral oncogene to lymphoma development is poorly understood.
|
18566961 |
2008 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The latency II program is limited to the expression of the nonimmunodominant antigens EBNA1, LMP1 and LMP2 and is seen in EBV-positive Hodgkin disease, nasopharyngeal carcinomas, and peripheral T/NK-cell lymphomas.
|
17471168 |
2007 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The oncogenic latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is involved in the pathogenesis of human nasopharyngeal carcinoma (NPC) and lymphoma.
|
23939952 |
2014 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
However, in both LMP1-positive and -negative lymphomas, only the oncogenic NF-kappaB c-Rel, was specifically activated.
|
16247482 |
2006 |